The vasculitides consistof a spectrum of clinical syndromes havingin common necrotizing inflammation of the vascularsystem. Typical classification systems are based on both size of vessel involved and clinical gestalt. The author favorsa pragmatic classification. Symptoms are manifestations of systemic inflammation and of organ ischemia secondary to inflammatory vascular occlusion. Multicenter studies suggest that the most common vasculitides do not satisfy criteria for one of the specific nosological entities and would be classified as "other" vasculitides. For thosesyndromes fitting a classical description (e.g., Wegener's, polyarteritis nodosa, Henoch-Schoenlein purpura), therapy is straight-forward. For those defying classification, therapy must be empirically directed at the manifestations causing symptoms.
INTRODUCTION
The human vasculitis syndromes have in common 'the inflammatory, and at times necrotizing, involvement of blood vessel walls. The type of vessel involved varies between syndromes from the venulitis ofleukocytoclastic vasculitis to the aortitis ofTakayasu's arteritis. Many ofthe vasculitides seem to share little other than inflammation of the vessel wall; therefore, it is in attempting to invoke a common pathogenic mechanism for all vasculitides that the scientist encounters trouble.
The human vasculitides most studied are those causing the most devastating, clinically apparent abnormalities. It is the author's belief that the most prevalent vasculitis in humans is benign cutaneous vasculitis resulting from exposure to medicines or other environmental agents, and that most of these are treated by family generalists or dermatologists by discontinuing the suspect medication without the patient ever reaching the tertiary centers from whence published series come. Therefore, it is likely that the spectrum of human vasculitides includes a substantial subclinical base of transient, mild abnormalities which rarely attain clinical significance.
The possible existence of such a subclinical base becomes seriously problematical in animal studies of drug toxicity, where extensive biopsy and necropsy specimens are taken. As detailed elsewhere in this symposium, a number of animal species, including the dog and the rat, are known to have clinically inapparent vasculitis of assorted organ systems discovered upon extensive necropsy. When such animals are exposed to investigational new drugs and later found to have microscopic vasculitis, it is difficult to ascribe causality because of the background prevalance of spontaneous, subclinical vasculitis. These microscopic changes may be related to infection with identifiable parasites or micro-organisms, but often occur in the absence of such identifiable etiologies. It is a major concern of this symposium to deal with that dilemma. PATHOGENESIS While in animals, the etiopathogenesis of vasculitis can sometimes be ascribed to acute effects of the invading organism upon the vascular system (e.g., equine arteritis) or the body's response to infection by a specific agent (e.g., Aleutian mink disease, lymphocytic choriomeningitis); such is rarely the case in human illness. Most of the proposed models assume that vasculitis results from a secondary response to an organism or chemical agent, with an immunological response being most often invoked.
Perhaps the best model for vasculitis is that of serum sickness. Animals given an intravenous injection ofa heterologous serum albumin will mount an immune response within 7-10 days. The newly synthesized antibody combines with circulating antigen, forming intravascular immune complexes, with resultant acceleration of reticuloendothelial clearance of that antigen. During this phase of immune complex circulation, immune deposit ne-.phritis with proteinuria, vasculitis and hypocomplementemia will occur. When the antibody response becomes sufficient to cause removal ofall circulating antigen, the process spontaneously and permanently ameliorates. If daily, chronic circulating antigenemia is maintained, chronic immune complex disease and death from chronic renal failure can occur. In early work (6) , optimal predisposition to chronic immune complex disease occurred in animals whose immune system recognized the circulating albumin neither as a tolerogen (in which case no antibody response occurred) nor as a strong immunogen (in which case rapid reticuloendothelial clearance occurred). Disease-prone animals were only partially tolerant to the circulating antigen, mounted an "incomplete" immune response, and cleared the antigen less rapidly. Comparable examples in nature include the immune response to native DNA that occurs in systemic lupus erythematosus. Doublestranded DNA is normally a tolerogen in all species. Mice and humans afflicted with lupus erythematosus have difficulty maintaining immune tolerance and mount an immune response which predisposes them to immune complex vasculitis and nephritis.
In subacute bacterial endocarditis, antigen persists in spite of an immune response and is released chronically into the blood stream from infected intravascular sites. If such situations are not treated with appropriate antibiotics, circulating immune complexes, mixed cryoglobulins, immune complex nephritis, and renal failure often result. In patients chronically infected with hepatitis B virus, intracellular sequestration of viral genome may result in periodic release ofvirus-related antigen and explain the mixed cryoglobulinemia and polyarteritis nodosa syndrome sometimes seen in such patients. The symptoms ofvasculitis include systemic ones such as fever, anorexia, night sweats, and, weight loss which result from sustained and widespread inflammation, as well as local symptoms due to involvement of specific vessels in specific organ systems. The clinical expression of that local injury includes the 4 events listed in Table I in purpura. Edematous narrowing can cause angina, Raynaud's symptoms, or actual infarction, as can residual scarring of the vessel wall. Thus, the presenting manifestations can range from palpable purpura to bowel infarction or a cerebral vascular accident as indicated in Table II . CLASSIFICATION One classification scheme based on the size ofthe vessel involved is shown in Fig. I .
A multicenter study to define criteria for the various vasculitides is being conducted by the American Rheumatism Association (ARA). Submissions to that study as of 1987 are shown in Table III and indicate that the bulk of submissions have been in the category called "other." Ifone reviews the classic literature on polyarteritis nodosa, the first systemic vasculitis to be carefully described by Kussmaul and Maier-in the late 1800s (4), the prevalence of organ system involvement is extensive as shown in Table  IV . Such percentagesare misleading, however, since: a) they represent "classic" cases and thus, the tip of the polyarteritis iceberg; and b) they represent organ system involvement at the time of referral to the reporting investigator and give no indication of symptoms or organ systems at the time of disease onset.
It is this author's contention, in fact, that the most common type of vasculitis in medicine consists of cutaneous vasculitis. This type is most often seen by dermatologists, does not involve other organ systems and therefore, never appears in the reviews of the systemic vasculitides. In describing 82 cases of cutaneous vasculitis, Ekenstam and Callen (2) found that slightly over half were idiopathic while the remainder were associated with a broad spectrum of conditions including rheumatoid arthritis, drug exposure, infection, and others (Table V) .
The primary utility of classifying the vasculitides by syndrome has been to predict prognosis and therefore to optimize therapy. Thus, the classical case of polyarteritis nodosa (see Table IV ) can be differentiated from the classical case of Wegener's (Table VI) with its necrotizing, granulomatous airway involvement. Similarly, the typical case of Henoch-Schoenlein (Table VII) vasculitis with lower extremity and gastrointestinal purpura and generally non-progressive glomerulitis warrants identification largely because of its benign clinical course.
The experience ofthe ARA subcommittee on the classification of vasculitis and anecdotal incidents, as related to the author by those in practice, suggests that many systemic vasculitides are not so easily classified. Leavitt and Fauci (5) were the first to document the existence of that vasculitis overlap syndrome in 10 patients who had mixed pictures, including the co-existenceof Takayasu's disease with polyarteritis nodosa, giant cell arteritis, and Wegener's, Henoch-Schoenlein purpura with polyarteritis nodosa and others. Thus, if earlier reviews described 1) Can we identify a classical underlying disease whose pathophysiology, prognosis, and management are well delineated? or 2) Can we identify a classical syndrome complex whose prognosis is known empirically to be markedly affected by our management (e.g., Wegener's)? or 3) Other tips of the nosological icebergs, more recent studies suggest that some of these icebergs may be connected beneath the surface of the diagnostic sea.
For this reason, the author prefers a pragmatic classificationsystem for the vasculitides (Table VIII) . First, one should attempt to identify a classical underlying illness, whose pathophysiology, prognosis and management have been well delineated. Examples would be systemic lupus erythematosus or rheumatoid arthritis associated with vasculitis. If this is not possible, the second step would be to identify a classical human vasculitis syndrome complex whose prognosis is known to be markedly affected by therapy. An example would be Wegener's granulomatosis, which responds dramatically to alkylating agents, or Henoch-Schoenlein disease which is best managed by expectant observation. Ifneither of the above 2 strategies is successful, a vasculitis should be considered as "Other."
DIAGNOSIS
The diagnosis of vasculitis is made in a logical, step-wise fashion (Table IX) . First, attempts should be made to diagnose any classical underlying disease by the performance of antinuclear antibody, anti-DNA, hemolytic complement, cryoglobulin, rheumatoid factor, and protein electrophoresis determinations. This will identify patients likely to have SLE, essential cryoglobulinemias, hypocomplementemic urticarial human vasculitis syndromes, rheumatoid disease, and monoclonal gammopathies. It is important to recognize that a number of nonvasculitic syndromes (listed in Table X) can mimic precisely all ofthe clinical and many ofthe serologic concomitants of immune complex vasculitis, including hypocomplementemia and presence of antinuclear or anti-DNA antibody. Accordingly, echocardiography to search for valvular vegetations of myxoma, blood cultures for endocarditis, or angiography to detect embolizing atheromata may be reasonable in appropriate instances. Ifthese are negative, an attempt should be made to find the extent of organ system involvement. In addition to urine and stool exams, sinus films, chest roentgenograms, electromyograms and nerve conduction velocities, EKGs and serum creatine phosphokinase levels may point to involvement ofspecific organs. One should then attempt to identify vasculitis in the organ system which seems most predominantly involved on the basis of those preliminary studies. This usually will require a biopsy of the involved system and it is clear that the yield of positive biopsy results is high when preliminary tests point to involvement of that organ. Thus, muscle, nerve, kidney, lung, skin, or nasal mucosal biopsy may be indicated. If a biopsy is not feasible or is negative, angiograrns of the viscera should be performed to look for the aneurysmal changes seen in vasculitis.
THERAPY
Therapy is largely empirical and, as mentioned above, is based on a foreknowledge of the natural history ofa given syndrome when one is identifiable. In general, acute inflammatory changes are most rapidly reversed by the use of high-dose steroids (60-80 milligrams prednisone or its equivalent per day). Chronic management relies on the use of immunosuppressive or alkylating drugs, such as azathioprine, cyclophosphamide, or chlorambucil. A possible exception to the use ofsteroids is the patient who clearly has Wegener's granulomatosis. These patients routinely did rather poorly during the steroid era and respond dramatically to alkylatingagents such as cyclophosphamide. In the absence of lifethreatening inflammatory problems, such patients are probably ideally treated first with cyclophosphamide in gradually increasing doses as tolerated to a maximum of 2 mg per kilogram per day (3).
PROGNOSIS
Factors affecting the prognosis in human vasculitis syndromes include (Table XI) : 1) The role of the involved organ in sustaining life. For example, involvement of the heart or brain obviously bodes less well than cutaneous involvement. 2) The reserve capacity of the organ involved. For example, the kidney has superb reserve capacity and can compensate for considerable impairment.
3) The reversibility of the ischemia present. Thus, necrosis of tissue due to infarction is unlikely to be reversed by therapy. 4) The capacity of the organ involved for self-repair. Thus, central nervous system infarcts are generally permanent, whereas the skin has considerable ability for healing.
The Mayo Clinic has examined factors affecting survival in 50 patients with polyarteritis nodosa (1). Of the various factors studied, the most impressive differential effect on survival was the presence of gastrointestinal involvement. This would seem reasonable, since gut infarction would immediately predispose to gram negative and anaero~ic peritoneal infection and sepsis, response to WhICh would be impaired by the very drugs used to treat vasculitis, steroids and immunosuppressives. There would obviously be no such risk of infection due to vasculitis in the peripheral nervous system, the kidneys, or the muscles.
Proper management ofthe patient with vasculitis requires that the clinician be knowledgeable about the potentially protean presenting manifestations, pursue an aggressiveattempt to identify human vasculitis syndrome with serologic studies, an appropriate biopsy and angiography, and initiate aggressive steroid or immunosuppressive therapy early to minimize irreversible infarction. 1) Role of involved organ in sustaining function of the organism (e.g., heart or brain vs skin) 2) Reserve capacity of organ involved (e.g., kidney) 3) Reversibility of ischemia (e.g., infarct vs reversible ischemia) 4) Capacity of involved organ for self-repair (e.g., brain vs skin)
EXTRAPOLATION FROM HUMANS TO ANIMALS
It is simply not possible to extrapolate easily our knowledgeand approach to diagnosis and treatment of human vasculitides to those found in clinically well, but extensively necropsied, animal species. Human diseases are studied in direct proportion to the severity of their morbidity and mortality. Microscopic vasculitis in dogs often appears to be a non-specific and unexpected finding ofquestionable clinical significance. Its prevalance in control animals is approximately that seen in drug-treated experimental groups. In order to establish that vasculitis in the latter groups is a result ofdrug exposure, a prohibitively large number of individual animals would have to be studied. Given the likelihood that there is a large cohort of humans with transient, benign and self-limited vasculitis, it is unreasonable to conclude that microscopic vasculitis in extensively studied experimental animals should be equated with devastating arteritides such as polyarteritis nodosa or Wegener's granulomatosis in humans.
